Asuragen, Inc. Enters Into Licensing Agreement With Yale University For Therapeutic Use Of let-7 miRNA

AUSTIN, Texas--(BUSINESS WIRE)--Asuragen Inc. ("Asuragen") announced today that it recently entered into a license agreement with Yale University for exclusive access to rights in inventions developed by Dr. Frank Slack for the regulation of oncogenes by microRNA’s.

Back to news